[1]

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, et al. 2024. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 74:229−263

doi: 10.3410/f.739487650.793592245
[2]

Sundar R, Nakayama I, Markar SR, Shitara K, van Laarhoven H, et al. 2025. Gastric cancer. The Lancet 405:2087−2102

doi: 10.1016/S0140-6736(25)00052-2
[3]

Takayama T, Tsuji Y. 2023. Updated Adjuvant Chemotherapy for Gastric Cancer. Journal of Clinical Medicine 12:6727

doi: 10.3390/jcm12216727
[4]

Kang YK, Terashima M, Kim YW, Boku N, Chung HC, et al. 2024. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. The Lancet Gastroenterology & Hepatology 9:705−717

doi: 10.1016/S2468-1253(24)00156-0
[5]

Wang FH, Zhang XT, Tang L, Wu Q, Cai MY, et al. 2024. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Communications 44:127−172

doi: 10.1002/cac2.12516
[6]

Hirata Y, Noorani A, Song S, Wang L, Ajani JA. 2023. Early stage gastric adenocarcinoma: clinical and molecular landscapes. Nature Reviews Clinical Oncology 20:453−469

doi: 10.1038/s41571-023-00767-w
[7]

Ma H, Srivastava S, Ho SWT, Xu C, Lian BSX, et al. 2025. Spatially resolved tumor ecosystems and cell states in gastric adenocarcinoma progression and evolution. Cancer Discov 15:767−792

doi: 10.1158/2159-8290.CD-24-0605
[8]

Cheng X, Dai E, Wu J, Flores NM, Chu Y, et al. 2024. Atlas of metastatic gastric cancer links ferroptosis to disease progression and immunotherapy response. Gastroenterology 167:1345−1357

doi: 10.1053/j.gastro.2024.07.038
[9]

Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, et al. 2015. Robust enumeration of cell subsets from tissue expression profiles. Nature Methods 12:453−7

doi: 10.1038/nmeth.3337
[10]

Aran D, Hu Z, Butte AJ. 2017. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biology 18:220

doi: 10.1186/s13059-017-1349-1
[11]

Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, et al. 2016. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biology 17:218

doi: 10.1186/s13059-016-1070-5
[12]

Li B, Severson E, Pignon JC, Zhao H, Li T, et al. 2016. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biology 17:174

doi: 10.1186/s13059-016-1028-7
[13]

Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, et al. 2019. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Medicine 11:34

doi: 10.1186/s13073-019-0638-6
[14]

Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, et al. 2017. Pan-cancer Immunogenomic Analyses Reveal Genotype- Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep 18:248−62

doi: 10.1016/j.celrep.2016.12.019
[15]

Zeng D, Li M, Zhou R, Zhang J, Sun H, et al. 2019. Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures. Cancer Immunology Research 7:737−750

doi: 10.1158/2326-6066.CIR-18-0436
[16]

Zeng D, Wu J, Luo H, Li Y, Xiao J, et al. 2021. Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer. Journal for Immunotherapy of Cancer 9:e002467

doi: 10.1136/jitc-2021-002467
[17]

Shi M, Zeng D, Luo H, Xiao J, Li Y, et al. 2024. Tumor microenvironment RNA test to predict immunotherapy outcomes in advanced gastric cancer: The TIMES001 trial. Med 5:1378−1392.e3

doi: 10.1016/j.medj.2024.07.006
[18]

Duan R, Li X, Zeng D, Chen X, Shen B, et al. 2020. Tumor microenvironment status predicts the efficacy of postoperative chemotherapy or radiochemotherapy in resected gastric cancer. Frontiers in Immunology 11:609337

doi: 10.3389/fimmu.2020.609337
[19]

Wang D, Wang N, Li X, Chen X, Shen B, et al. 2021. Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia. Gastric Cancer 24:823−834

doi: 10.1007/s10120-021-01175-8
[20]

Li Y, Li X, Yang Y, Qiao X, Tao Q, et al. 2023. Association of genes in hereditary metabolic diseases with diagnosis, prognosis, and treatment outcomes in gastric cancer. Frontiers in Immunology 14:1289700

doi: 10.3389/fimmu.2023.1289700
[21]

Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, et al. 2014. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568−71

doi: 10.1038/nature13954
[22]

Kzhyshkowska J, Shen J, Larionova I. 2024. Targeting of TAMs: can we be more clever than cancer cells? Cellular & Molecular Immunology 21:1376−1409

doi: 10.1038/s41423-024-01232-z
[23]

Bai X, Guo YR, Zhao ZM, Li XY, Dai DQ, et al. 2025. Macrophage polarization in cancer and beyond: from inflammatory signaling pathways to potential therapeutic strategies. Cancer Letters 625:217772

doi: 10.1016/j.canlet.2025.217772
[24]

Kloosterman DJ, Akkari L. 2023. Macrophages at the interface of the co-evolving cancer ecosystem. Cell 186:1627−1651

doi: 10.1016/j.cell.2023.02.020
[25]

Jiang Y, Wang Y, Chen G, Sun F, Wu Q, et al. 2024. Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer. Cell Metabolism 36:1806−1822.e11

doi: 10.1016/j.cmet.2024.05.013
[26]

Cantoni C, Falco M, Vitale M, Pietra G, Munari E, et al. 2024. Human NK cells and cancer. Oncoimmunology 13:2378520

doi: 10.1080/2162402X.2024.2378520
[27]

Netskar H, Pfefferle A, Goodridge JP, Sohlberg E, Dufva O, et al. 2024. Pan-cancer profiling of tumor-infiltrating natural killer cells through transcriptional reference mapping. Nature Immunology 25:1445−1459

doi: 10.1038/s41590-024-01884-z